Please use this identifier to cite or link to this item:
https://doi.org/10.1038/s41408-021-00544-x
| Title: | A phase 2 study of carfilzomib, cyclophosphamide and dexamethasone as frontline treatment for transplant-eligible MM with high-risk features (SGH-MM1) | Authors: | Chen, Yunxin Gopalakrishnan, Sathish Kumar Ooi, Melissa Sultana, Rehena Lim, Li Hui Grigoropoulos, Nicholas Ong, Shin Yeu Xu, Mingge Chng, Wee Joo Goh, Yeow Tee Nagarajan, Chandramouli |
Keywords: | Science & Technology Life Sciences & Biomedicine Oncology Hematology MULTIPLE-MYELOMA LENALIDOMIDE |
Issue Date: | 3-Sep-2021 | Publisher: | SPRINGERNATURE | Citation: | Chen, Yunxin, Gopalakrishnan, Sathish Kumar, Ooi, Melissa, Sultana, Rehena, Lim, Li Hui, Grigoropoulos, Nicholas, Ong, Shin Yeu, Xu, Mingge, Chng, Wee Joo, Goh, Yeow Tee, Nagarajan, Chandramouli (2021-09-03). A phase 2 study of carfilzomib, cyclophosphamide and dexamethasone as frontline treatment for transplant-eligible MM with high-risk features (SGH-MM1). BLOOD CANCER JOURNAL 11 (9). ScholarBank@NUS Repository. https://doi.org/10.1038/s41408-021-00544-x | Source Title: | BLOOD CANCER JOURNAL | URI: | https://scholarbank.nus.edu.sg/handle/10635/207736 | ISSN: | 20445385 2044-5385 |
DOI: | 10.1038/s41408-021-00544-x |
| Appears in Collections: | Elements Staff Publications |
Show full item record
Files in This Item:
| File | Description | Size | Format | Access Settings | Version | |
|---|---|---|---|---|---|---|
| A phase 2 study of carfilzomib, cyclophosphamide and dexamethasone as frontline treatment for transplant-eligible MM with hi.pdf | 895.33 kB | Adobe PDF | OPEN | Published | View/Download |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.